HOME › DRUGS › TIRZEPATIDE
ACTIVE SUBSTANCE / INN

TIRZEPATIDE

Brand name(s): ZEPBOUND (AUTOINJECTOR), MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, MOUNJARO, Mounjaro, ZEPBOUND KWIKPEN
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
NDA215866
Diabetes Mellitus, Type 2;Obesity;Overweight
ACTIVE SUBSTANCE
Tirzepatide
REGULATORS
FDA · EMA
SPONSORS / MAH
Eli Lilly Nederland B.V., ELI LILLY AND CO
TOTAL APPLICATIONS
7
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
ZEPBOUNDNDA217806ELI LILLY AND COPrescription
ZEPBOUND KWIKPENNDA217806ELI LILLY AND COPrescription
ZEPBOUND (AUTOINJECTOR)NDA217806ELI LILLY AND COPrescription
MOUNJARONDA215866ELI LILLY AND COPrescription
MOUNJARO KWIKPENNDA215866ELI LILLY AND COPrescription
MOUNJARO (AUTOINJECTOR)NDA215866ELI LILLY AND COPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
MounjaroEli Lilly Nederland B.V.Authorised15/09/2022Diabetes Mellitus, Type 2;Obesity;Overweight

FULL INTELLIGENCE ON TIRZEPATIDE

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →